Cargando…

Impact of COVID-19 on Radiation Oncology, an Austrian Experience

The COVID-19 pandemic has an unprecedented impact on cancer treatment worldwide. We aimed to evaluate the effects of the pandemic on the radiation treatment of patients in order to provide data for future management of such crises. We compared the number of performed radiotherapy sessions of the pan...

Descripción completa

Detalles Bibliográficos
Autores principales: Mangesius, Julian, Arnold, Christoph Reinhold, Seppi, Thomas, Mangesius, Stephanie, Brüggl, Mario, Eichberger, Paul, Ganswindt, Ute
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8628691/
https://www.ncbi.nlm.nih.gov/pubmed/34898552
http://dx.doi.org/10.3390/curroncol28060404
_version_ 1784607047910686720
author Mangesius, Julian
Arnold, Christoph Reinhold
Seppi, Thomas
Mangesius, Stephanie
Brüggl, Mario
Eichberger, Paul
Ganswindt, Ute
author_facet Mangesius, Julian
Arnold, Christoph Reinhold
Seppi, Thomas
Mangesius, Stephanie
Brüggl, Mario
Eichberger, Paul
Ganswindt, Ute
author_sort Mangesius, Julian
collection PubMed
description The COVID-19 pandemic has an unprecedented impact on cancer treatment worldwide. We aimed to evaluate the effects of the pandemic on the radiation treatment of patients in order to provide data for future management of such crises. We compared the number of performed radiotherapy sessions of the pandemic period from February 2020 until May 2021 with those of 2018 and 2019 for reference. At our department, no referred patients had to be rejected or postponed, nor any significant changes in fractionation schedules implemented. Nevertheless, there was a substantial drop in overall radiotherapy sessions in 2020 following the first incidence wave of up to −25% (in June) in comparison to previous years. For breast cancer, a maximum decline of sessions of −45% (July) was recorded. Only a short drop of prostate cancer sessions (max −35%, May) followed by a rebound (+42%, July) was observed. Over the investigated period, a loss of 4.4% of expected patients never recovered. The severe impact of COVID-19 on cancer treatment, likely caused by retarded diagnosis and delayed interdisciplinary co-treatment, is reflected in a lower count of radiotherapy sessions. Radiation oncology is a crucial cornerstone in upholding both curative treatment options and treatment capacity during a pandemic.
format Online
Article
Text
id pubmed-8628691
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86286912021-11-30 Impact of COVID-19 on Radiation Oncology, an Austrian Experience Mangesius, Julian Arnold, Christoph Reinhold Seppi, Thomas Mangesius, Stephanie Brüggl, Mario Eichberger, Paul Ganswindt, Ute Curr Oncol Article The COVID-19 pandemic has an unprecedented impact on cancer treatment worldwide. We aimed to evaluate the effects of the pandemic on the radiation treatment of patients in order to provide data for future management of such crises. We compared the number of performed radiotherapy sessions of the pandemic period from February 2020 until May 2021 with those of 2018 and 2019 for reference. At our department, no referred patients had to be rejected or postponed, nor any significant changes in fractionation schedules implemented. Nevertheless, there was a substantial drop in overall radiotherapy sessions in 2020 following the first incidence wave of up to −25% (in June) in comparison to previous years. For breast cancer, a maximum decline of sessions of −45% (July) was recorded. Only a short drop of prostate cancer sessions (max −35%, May) followed by a rebound (+42%, July) was observed. Over the investigated period, a loss of 4.4% of expected patients never recovered. The severe impact of COVID-19 on cancer treatment, likely caused by retarded diagnosis and delayed interdisciplinary co-treatment, is reflected in a lower count of radiotherapy sessions. Radiation oncology is a crucial cornerstone in upholding both curative treatment options and treatment capacity during a pandemic. MDPI 2021-11-17 /pmc/articles/PMC8628691/ /pubmed/34898552 http://dx.doi.org/10.3390/curroncol28060404 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Mangesius, Julian
Arnold, Christoph Reinhold
Seppi, Thomas
Mangesius, Stephanie
Brüggl, Mario
Eichberger, Paul
Ganswindt, Ute
Impact of COVID-19 on Radiation Oncology, an Austrian Experience
title Impact of COVID-19 on Radiation Oncology, an Austrian Experience
title_full Impact of COVID-19 on Radiation Oncology, an Austrian Experience
title_fullStr Impact of COVID-19 on Radiation Oncology, an Austrian Experience
title_full_unstemmed Impact of COVID-19 on Radiation Oncology, an Austrian Experience
title_short Impact of COVID-19 on Radiation Oncology, an Austrian Experience
title_sort impact of covid-19 on radiation oncology, an austrian experience
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8628691/
https://www.ncbi.nlm.nih.gov/pubmed/34898552
http://dx.doi.org/10.3390/curroncol28060404
work_keys_str_mv AT mangesiusjulian impactofcovid19onradiationoncologyanaustrianexperience
AT arnoldchristophreinhold impactofcovid19onradiationoncologyanaustrianexperience
AT seppithomas impactofcovid19onradiationoncologyanaustrianexperience
AT mangesiusstephanie impactofcovid19onradiationoncologyanaustrianexperience
AT brugglmario impactofcovid19onradiationoncologyanaustrianexperience
AT eichbergerpaul impactofcovid19onradiationoncologyanaustrianexperience
AT ganswindtute impactofcovid19onradiationoncologyanaustrianexperience